Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria, Via Altura 1/8, 40139, Bologna, Italy.
Acta Neuropathol Commun. 2019 Apr 8;7(1):53. doi: 10.1186/s40478-019-0706-6.
Current evidence indicating a role of the human prion protein (PrP) in amyloid-beta (Aβ) formation or a synergistic effect between Aβ and prion pathology remains controversial. Conflicting results also concern the frequency of the association between the two protein misfolding disorders and the issue of whether the apolipoprotein E gene (APOE) and the prion protein gene (PRNP), the major modifiers of Aβ- and PrP-related pathologies, also have a pathogenic role in other proteinopathies, including tau neurofibrillary degeneration. Here, we thoroughly characterized the Alzheimer's disease/primary age-related tauopathy (AD/PART) spectrum in a series of 450 cases with definite sporadic or genetic Creutzfeldt-Jakob disease (CJD). Moreover, we analyzed: (i) the effect of variables known to affect CJD pathogenesis and the co-occurring Aβ- and tau-related pathologies; (II) the influence of APOE genotype on CJD pathology, and (III) the effect of AD/PART co-pathology on the clinical CJD phenotype. AD/PART characterized 74% of CJD brains, with 53.3% and 8.2% showing low or intermediate-high levels of AD pathology, and 12.4 and 11.8% definite or possible PART. There was no significant correlation between variables affecting CJD (i.e., disease subtype, prion strain, PRNP genotype) and those defining the AD/PART spectrum (i.e., ABC score, Thal phase, prevalence of CAA and Braak stage), and no difference in the distribution of APOE ε4 and ε2 genotypes among CJD subtypes. Moreover, AD/PART co-pathology did not significantly affect the clinical presentation of typical CJD, except for a tendency to increase the frequency of cognitive symptoms. Altogether, the present results seem to exclude an increased prevalence AD/PART co-pathology in sporadic and genetic CJD, and indicate that largely independent pathogenic mechanisms drive AD/PART and CJD pathology even when they coexist in the same brain.
目前,关于人类朊病毒蛋白(PrP)在淀粉样β(Aβ)形成中的作用,或者 Aβ 和朊病毒病理学之间的协同作用,仍存在争议。相互矛盾的结果也涉及到这两种蛋白错误折叠疾病之间的关联频率,以及载脂蛋白 E 基因(APOE)和朊病毒蛋白基因(PRNP),即 Aβ 和 PrP 相关病理学的主要修饰因子,是否也在其他蛋白病(包括tau 神经原纤维缠结)中具有致病性作用。在这里,我们通过对一系列 450 例明确的散发性或遗传性克雅氏病(CJD)病例进行了彻底的分析,对阿尔茨海默病/原发性年龄相关性tau 病(AD/PART)谱进行了研究。此外,我们还分析了:(i)已知影响 CJD 发病机制的变量,以及同时存在的 Aβ 和 tau 相关病理学;(ii)APOE 基因型对 CJD 病理学的影响;(iii)AD/PART 共病对 CJD 临床表型的影响。AD/PART 特征存在于 74%的 CJD 大脑中,其中 53.3%和 8.2%显示低或中高水平的 AD 病理学,12.4%和 11.8%分别为明确或可能的 PART。影响 CJD(即疾病亚型、朊病毒株、PRNP 基因型)的变量与定义 AD/PART 谱(即 ABC 评分、Thal 期、CAA 的患病率和 Braak 期)的变量之间没有显著相关性,CJD 亚型之间 APOE ε4 和 ε2 基因型的分布也没有差异。此外,AD/PART 共病对典型 CJD 的临床表现没有显著影响,除了认知症状的频率有增加的趋势。总的来说,目前的结果似乎排除了散发性和遗传性 CJD 中 AD/PART 共病发病率增加的可能性,并表明即使在同一大脑中存在 AD/PART 和 CJD 病理学,也存在着驱动 AD/PART 和 CJD 病理学的主要独立的致病机制。